Calidi Biotherapeutics Inc. CLDI Archives

FridayAug 22, 2025 9:00 am

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted therapies to deliver genetic medicines to distal sites of disease, announced the closing of its underwritten public offering and the full exercise of the underwriters’ over-allotment option for gross proceeds of $6.9 million before deducting commissions and expenses. The Company sold 1,922,764 common stock units, each consisting of one share and one Series I warrant, and 1,528,000 pre-funded warrant units, each consisting of one pre-funded warrant and one Series I warrant. The offering included 450,000 common stock units purchased under the over-allotment option. Common Stock Units were priced at…

MondayAug 11, 2025 9:10 am

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Q2 2025 Results and Business Highlights

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted therapies to deliver genetic medicines to metastatic disease sites, reported a Q2 2025 net loss of $5.7 million, or $1.99 per share, compared to a net loss of $7.4 million, or $16.75 per share, in Q2 2024. R&D expenses were $2.6 million versus $2.2 million last year, while G&A expenses were $3.1 million compared to $3.6 million. Calidi ended the quarter with $5.3 million in cash and $0.1 million in restricted cash. Recent highlights include new preclinical data on CLD-401 from the proprietary RedTail platform, showing enhanced efficacy through…

FridayJul 11, 2025 9:00 am

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in NetworkNewsWire Spotlight on Genetic Medicines

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech innovator, announced its inclusion in an editorial by NetworkNewsWire titled “Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers.” The article highlights Calidi’s next-generation platform, which uses engineered viruses to deliver genetic therapies directly to primary and metastatic tumors. While oncology is the company's initial focus, it is also evaluating applications in autoimmune disorders, underscoring its broader therapeutic potential. The editorial emphasizes Calidi’s role in addressing the rising global cancer burden and advancing transformative treatment options. To view the full press release, visit: https://ibn.fm/jHVW2 About Calidi Biotherapeutics Calidi Biotherapeutics is a clinical-stage immuno-oncology…

FridayJun 27, 2025 10:20 am

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company developing systemic oncolytic targeted immunotherapies, released a shareholder letter from CEO Eric Poma, PhD, outlining a transformative year for the company. Since Poma’s appointment in April 2025 and the addition of Dr. Guy Travis Clifton as Chief Medical Officer, Calidi has streamlined operations and advanced its RedTail platform—a systemically delivered virotherapy designed to target metastatic cancers and deliver genetic payloads. Preclinical data presented at AACR and ASCO showcased RedTail’s tumor selectivity and immune modulation potential, driving partnership discussions and IND-enabling studies for lead candidate CLD-401, with a filing expected by end…

TuesdayJun 10, 2025 3:20 pm

QualityStocksNewsBreaks – Nightfood Holdings Inc. (NGTF): Where Hospitality Meets High Tech

Nightfood Holdings (OTCQB: NGTF) is redefining the hospitality experience by blending artificial intelligence, robotics, and predictive analytics to help hoteliers deliver seamless, personalized service amid labor shortages and rising guest expectations. As one of the few publicly traded companies uniquely positioned at the intersection of hospitality and AI, NGTF offers a compelling investment opportunity. Through its subsidiaries, NGTF provides cutting-edge Robotics-as-a-Service (“RaaS”) solutions and is acquiring hotel properties to serve as live tech showcases. More than a service provider or tech vendor, Nightfood is a catalyst for the next era of hospitality—championing a human-centric, automation-driven future that empowers hotels to thrive.…

TuesdayJun 10, 2025 12:58 pm

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Taps Biotech Veteran to Lead Next Phase of Growth

Calidi Biotherapeutics (NYSE American: CLDI) recently announced the appointment of Eric Poma, PhD, as its new chief executive officer and member of the board of directors. The company was featured in an article that reads, “As Calidi Biotherapeutics continues to pioneer targeted antitumor virotherapies, the appointment of Dr. Poma as CEO represents a strategic move to harness experienced leadership for the company’s next phase of growth. His extensive background in oncology, successful track record in fundraising and strategic partnerships, and comprehensive understanding of the biotech landscape position him to effectively steer Calidi’s innovative therapies through clinical development and toward commercialization.” To…

ThursdayMay 22, 2025 3:00 pm

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) RTNova Shows Promise in Targeted Tumor Therapy

Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors. The innovative platform not only targets cancer cells effectively but also minimizes harm to surrounding healthy tissues, potentially improving treatment outcomes and reducing side effects. As global cancer rates continue to rise, Calidi’s RTNova platform and tumor-specific virotherapy hold the promise of offering new hope to cancer patients, addressing the limitations of existing treatments, and potentially improving survival rates across multiple cancer types. The company’s ongoing research and deep commitment to scientific excellence position…

MondayMay 19, 2025 9:00 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names Experienced Life Science Leader as New CEO

Experienced leadership contributes to key performance indicators. Dr. Eric Poma brings more than 30 years of experience to his new role as CLDI CEO. His expertise will help the company develop and advance proprietary groundbreaking therapies. Effective leadership is a cornerstone of organizational success, particularly in the dynamic and high-stakes realm of biotechnology. Recognizing the pivotal role of seasoned leadership, Calidi Biotherapeutics (NYSE American: CLDI) has announced the appointment of Eric Poma, PhD, as its new Chief Executive Officer and member of the board of directors (https://ibn.fm/qMEu4). This strategic transition underscores Calidi's commitment to advancing its innovative cancer therapies under experienced…

FridayMay 09, 2025 2:37 pm

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Eyes Game-Changing Approach to Cancer Treatment

Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its innovative RTNova platform, which has successfully delivered transient gene-therapy payloads to targeted tumors. In addition, Calidi’s virotherapy demonstrated efficacy in killing more than 60 different tumor cell lines, showcasing the platform’s potential to revolutionize cancer treatment by enabling both tumor destruction and robust immune activation. “Targeting tumors with a systemic virotherapy with a multimodal mechanism of action, which includes direct killing of the tumors and robust activation of antitumor immune responses, may revolutionize the way we approach cancer treatments,” said a Calidi spokesman. “We are excited to have shown…

WednesdayApr 30, 2025 10:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Committed to Advancing Cancer Care with Innovative RTNova Platform Research

Cancer statistics underscore the urgency of ongoing cancer research and the need for more effective cancer treatments. Calidi Biotherapeutics has announced preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors. The trials show an ability to deliver therapeutic payloads with precision while simultaneously attacking tumors. Cancer remains one of the deadliest diseases worldwide. Globally, the World Health Organization reports that the number of deaths will surpass 9.7 million in 2024, with a projected 20 million new cancer cases diagnosed; WHO also noted that it anticipates the cancer burden increasing an estimated 77% by…

Site Search

Company Search

Tag: Calidi Biotherapeutics Inc. CLDI